XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Stock Based Compensation
12 Months Ended
Jun. 30, 2024
Stock Based Compensation  
Stock Based Compensation

Note 12 — Stock Based Compensation and Payments

 

The equity incentive plan of the Company was established in February of 2017. The Board of Directors of the Company may from time to time, in its discretion grant to directors, officers, consultants and employees of the Company, non-transferable options to purchase common shares, provided that the number of options issued do not exceed 25,000,000. The options are exercisable for a period of up to 4 years from the date of the grant. The number of shares authorized to be issued under the equity incentive plan was increased from 10,000,000 to 25,000,000 through consent of stockholders to amend and restate the equity incentive plan. 

 

The average fair value of stock options granted was estimated to be $0.14 and $0.07 per share for the period ended June 30, 2024 and June 30, 2023. This estimate was made using the Black-Scholes option pricing model and the following weighted average assumptions:

 

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

Expected option life (years)

 

2-4

 

 

2 - 4

 

Expected stock price volatility

 

227to254

%

 

227to254

%

Expected dividend yield

 

 

-

 

 

 

 

Risk-free interest rate

 

0.44to0.54

%

 

0.44to0.54

%

A summary of option activity under the employee share option plan as of June 30, 2024 and 2023 and changes during the year then ended is presented below.

 

 

 

Shares

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Remaining

Contractual

Price

 

 

Aggregate

Intrinsic

Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options:

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at July 1, 2023

 

 

15,832,062

 

 

$0.06

 

 

 

 

 

 

 

Granted

 

 

2,500,000

 

 

$0.04

 

 

 

 

 

 

 

Exercised, converted

 

 

(558,062 )

 

$0.00

 

 

 

 

 

 

 

Forfeited / exchanged / modification

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Outstanding at July 1, 2023

 

 

17,774,000

 

 

$0.06

 

 

 

 

 

 

 

Granted

 

 

-

 

 

$0.00

 

 

 

 

 

 

 

Exercised, converted

 

 

-

 

 

$0.00

 

 

 

 

 

 

 

Forfeited / exchanged / modification

 

 

(13,624,000 )

 

$0.11

 

 

 

 

 

 

 

Outstanding at June 30, 2024

 

 

4,150,000

 

 

$0.08

 

 

 

0.5

 

 

$-

 

Exercisable at June 30, 2024

 

 

4,150,000

 

 

$0.08

 

 

 

0.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Number of options available for grant at end of period

 

 

10,617,326

 

 

 

 

 

 

 

 

 

 

 

 

 

 

A summary of the status of the Company’s nonvested shares as of and for the years ended June 30, 2024 and 2023 is presented below

 

Options

 

Shares

 

 

Weighted-Average

Grant-Date

Fair Value

 

Nonvested at July 1, 2023

 

 

13,450,170

 

 

$0.11

 

Granted

 

 

2,500,000

 

 

$0.04

 

Vested

 

 

(15,287,562 )

 

$0.07

 

Forfeited

 

 

-

 

 

 

-

 

Nonvested at July 1, 2023

 

 

662,608

 

 

$0.11

 

Granted

 

 

 

 

 

$-

 

Vested

 

 

(662,608 )

 

$0.11

 

Forfeited

 

 

-

 

 

$-

 

Nonvested at June 30, 2024

 

 

-

 

 

$0.00

 

 

Stock-based compensation expense attributable to stock options was approximately $280,665 and $360,105 for the years ended June 30, 2024 and 2023, respectively.

 

As of June 30, 2024 and 2023, there was approximately $47,535 and $328,200, respectively, of unrecognized compensation expense related to 141,170 and 13,450,170, respectively, nonvested stock options outstanding, and the weighted average vesting period for those options was 1 years.

Warrants

 

At June 30, 2023, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements. Information relating to these warrants is summarized as follows:

 

Warrants

 

Remaining

Number

Outstanding

 

 

Weighted

Average

Remaining

Life (Years)

 

 

Weighted

Average

Exercise

Price

 

Warrants - SEDA Financing

 

 

86,957

 

 

 

-

 

 

$1.15

 

Warrants - Issued with Convertible Notes

 

 

600,000

 

 

 

0.23

 

 

$0.75

 

Warrants - Securities Purchase Agreement

 

 

360,577

 

 

 

1.02

 

 

$0.78

 

Warrants A - Securities Purchase Agreement

 

 

28,072,364

 

 

 

1.02

 

 

$0.16

 

Total

 

 

29,119,898

 

 

 

 

 

 

 

 

 

Aggregate intrinsic value at June 30, 2023

 

$0

 

 

 

 

 

 

 

 

 

 

At June 30, 2024, the Company had outstanding warrants to purchase the Company’s common stock which were issued in connection with multiple financing arrangements. Information relating to these warrants is summarized as follows:

 

Warrants

 

Remaining

Number

Outstanding

 

 

Weighted

Average

Remaining

Life (Years)

 

 

Weighted

Average

Exercise

Price

 

Warrants - Securities Purchase Agreement

 

 

360,577

 

 

 

0.02

 

 

 

0.78

 

Warrants A - Securities Purchase Agreement

 

 

28,072,364

 

 

 

0.02

 

 

$0.17

 

Total

 

 

28,432,941

 

 

 

 

 

 

 

 

 

Aggregate intrinsic value at June 30, 2024

 

$0